Bank of New York Mellon Corp decreased its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 0.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,653 shares of the medical instruments supplier’s stock after selling 26 shares during the quarter. Bank of New York Mellon Corp owned 0.47% of Mesa Laboratories worth $2,529,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of MLAB. Pembroke Management LTD purchased a new position in shares of Mesa Laboratories in the second quarter valued at approximately $8,283,000. Thomson Horstmann & Bryant Inc. boosted its stake in shares of Mesa Laboratories by 75.4% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 72,362 shares of the medical instruments supplier’s stock valued at $10,370,000 after purchasing an additional 31,107 shares during the period. Bessemer Group Inc. boosted its stake in shares of Mesa Laboratories by 716.7% in the second quarter. Bessemer Group Inc. now owns 4,900 shares of the medical instruments supplier’s stock valued at $702,000 after purchasing an additional 4,300 shares during the period. Spark Investment Management LLC purchased a new position in shares of Mesa Laboratories in the second quarter valued at approximately $300,000. Finally, Eqis Capital Management Inc. boosted its stake in shares of Mesa Laboratories by 5.6% in the second quarter. Eqis Capital Management Inc. now owns 5,188 shares of the medical instruments supplier’s stock valued at $744,000 after purchasing an additional 273 shares during the period. 67.02% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Bank of New York Mellon Corp Sells 26 Shares of Mesa Laboratories, Inc. (MLAB)” was published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2017/10/13/bank-of-new-york-mellon-corp-sells-26-shares-of-mesa-laboratories-inc-mlab.html.
Several research firms have recently commented on MLAB. BidaskClub lowered shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. TheStreet lowered shares of Mesa Laboratories from a “b” rating to a “c+” rating in a research note on Monday, July 31st. Finally, Zacks Investment Research lowered shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research note on Thursday, August 3rd.
Mesa Laboratories, Inc. (NASDAQ:MLAB) opened at 149.82 on Friday. The stock has a market cap of $563.02 million, a P/E ratio of 53.85 and a beta of 0.49. Mesa Laboratories, Inc. has a 52 week low of $109.14 and a 52 week high of $169.80. The company has a 50-day moving average of $143.64 and a 200-day moving average of $141.63.
Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.56 by ($0.17). The company had revenue of $22.67 million during the quarter, compared to analysts’ expectations of $22.90 million. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. On average, analysts predict that Mesa Laboratories, Inc. will post $2.74 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Thursday, November 30th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Wednesday, November 29th. Mesa Laboratories’s dividend payout ratio is presently 22.94%.
In other Mesa Laboratories news, Director H Stuart Campbell sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $130.16, for a total value of $130,160.00. Following the completion of the transaction, the director now owns 42,366 shares in the company, valued at approximately $5,514,358.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 8,610 shares of company stock valued at $1,176,809. 15.70% of the stock is owned by company insiders.
About Mesa Laboratories
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.